Effect of extracorporeal membrane oxygenation on tobramycin pharmacokinetics in sheep.
METHODS
Critically ill infants undergoing extracorporeal membrane oxygenation (ECMO) therapy often receive multiple pharmacologic agents. Although the disposition of many drugs has been assessed in patients undergoing cardiopulmonary bypass and in patients receiving mechanical ventilation, only limited data exist for selected medications in patients undergoing ECMO. To evaluate the potential influence of ECMO on aminoglycoside pharmacokinetics, we studied the disposition of tobramycin in ten sheep before and during ECMO therapy. Each sheep received a single iv dose of tobramycin during a control period before ECMO and on a study day during ECMO. Identically timed serial blood samples over 4 hrs were obtained after each tobramycin dose. Paired serum tobramycin concentrations were obtained pre- and postmembrane oxygenator during ECMO in six sheep.


RESULTS
Alterations in specific pharmacokinetic variables for tobramycin were observed as a result of ECMO. Estimates of elimination half-life and volume of distribution for tobramycin were significantly increased during ECMO as compared with control (pre-ECMO) values (1.8 +/- 0.3 vs. 2.7 +/- 0.8 [SD] hrs [p < .01] and 0.3 +/- 0.1 vs. 0.5 +/- 0.2 L/kg [p < .005], respectively). Tobramycin body clearance was unaffected by the procedure (1.8 +/- 0.8 vs. 1.7 +/- 0.4 mL/min/kg). Paired serum tobramycin concentrations obtained pre- and postmembrane oxygenator demonstrated no drug removal.


CONCLUSIONS
These data suggest that ECMO circuitry does not sequester tobramycin and that the prolonged elimination half-life observed during ECMO therapy is not due to a change in drug clearance but is due to an ECMO-induced increase in tobramycin volume of distribution. To achieve and maintain preselected target tobramycin serum concentrations during ECMO, the usual dosage interval should remain unchanged, but the dose should be increased to compensate for the alteration in the drug's volume of distribution. The clinical applicability of these findings needs to be confirmed in carefully controlled clinical studies involving infants receiving ECMO therapy.
Möller
J C
JC
Division of Critical Care Medicine, Miami Children's Hospital, FL.
Gilman
J T
JT
Kearns
G L
GL
Sussmane
J B
JB
Raszynski
A
A
Wolfsdorf
J
J
Reed
M D
MD
D000818:Animals; D016638:Critical Illness; D004195:Disease Models, Animal; D016903:Drug Monitoring; D005069:Evaluation Studies as Topic; D015199:Extracorporeal Membrane Oxygenation / Q000592:standards*; D007262:Infusions, Intravenous; D016018:Least-Squares Analysis; D008657:Metabolic Clearance Rate; D011446:Prospective Studies; D012756:Sheep; D014018:Tissue Distribution; D014031:Tobramycin / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*
D014031:Tobramycin